Skip to main content
Premium Trial:

Request an Annual Quote

Geneseeq Nabs CE Marks for Residual Disease and Cancer Early Detection Tests

NEW YORK – Cancer diagnostics firm Geneseeq Technology said Tuesday that both its multi-cancer minimal residual disease detection (MRD) and multi-cancer early detection (MCED) kits have been CE-marked for use in solid tumor patients.

The Toronto-based company said this will enable it to expand its global business operations and establish new partnerships in the European market.

Geneseeq's MRD detection kit, dubbed Shielding, employs an ultra-deep sequencing technology that the firm calls ATG-SEQ to detect low levels of circulating tumor DNA in patients' peripheral blood after surgical removal of their tumor.

The company has published data on the use of this approach to predict recurrence in lung cancer patients.

For early cancer detection, Geneseeq has developed an in vitro diagnostic kit using a highly sensitive next-generation sequencing-based technology, called MERCURY, to assess multiomic features of circulating free DNA that distinguish tumorigenesis in asymptomatic individuals.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.